Glorimet PG 1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (1 mg), Metformin (500 mg), and Pioglitazone (15 mg) formulated for sustained release. This triple therapy is indicated for the management of type 2 diabetes mellitus in patients inadequately controlled by diet and exercise alone. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glycemic control without causing significant hypoglycemia. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ), which improves insulin sensitivity in adipose tissue, muscle, and the liver. The sustained-release formulation ensures a gradual release of active ingredients, promoting better tolerability and adherence by minimizing gastrointestinal side effects commonly associated with metformin. Glorimet PG 1 Tablet SR should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose levels. Caution is advised in patients with hepatic, renal, or cardiac impairment, and it is contraindicated in cases of diabetic ketoacidosis or severe renal dysfunction. Regular follow-up is essential to optimize therapeutic outcomes and monitor for potential adverse effects.